Disseminated tuberculosis in patient with rheumatoid arthritis after infliximab therapy [2];Tuberculosis miliar en un paciente con artritis reumatoide tratado con infliximab

Medicina Clinica

Volumn 119, Issue 16, 2002, Pages 636-637

  Ramos González, Antonio ^a   Corzo Delgado, Juan Enrique ^a   Sánchez Bursón, Juan ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; LACTATE DEHYDROGENASE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

AGED; CASE REPORT; CLINICAL FEATURE; COUGHING; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; HUMAN; LETTER; LUNG LAVAGE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RHEUMATOID ARTHRITIS; THORAX SCINTISCANNING;

EID: 0037049046     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73521-5     Document Type: Letter

References (10)

1. Lipsky PE, Van de Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
2. Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354: 1932-9.
4. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman W, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-103.
5. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al. Effects factor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-55.
6. Byrd TF. Tumor necrosis factor alpha promotes growth of virulent Mycobacterium tuberculosis in human monocytes. Iron-mediated growth suppression in correlated with decreased release of TNFa from iron-treated infected monocytes. J Clin Invest 1997;99:2518-29.
7. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-mediated uptake and tumor necrosis factor alfa-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994;152:743-53.
8. Pryhuber GS, Huyck HI, Staversky RJ, Finkelstein JN, O'Reilly MA. Tumor necrosis factor alfa-induced lung cells expression of antiapoptotic genes TRAF1 and clAP2. Am J Respir Cell Mol Biol 2000;22:150-6.
9. EMEA/4445/00 Public Statement on REMICADE (Infliximab). Reports of tuberculosis infections. Disponible en: http://www.emea.eu.int/htms/human/drugalert/ drugalert.htm
10. EMEA/21/12/00 Nota informativa de la Agencia Española del Medicamento sobre el riesgo de infección tuberculosa asociada a infliximab (Remicade®). Disponible en: http://www.msc.es/agemed/csmh/notas/infliximab.asp